Current Strategies and Future Prospects of Achondroplasia Treatment : A Systemic Review
DOI:
https://doi.org/10.12775/JEHS.2025.79.58212Keywords
Achondroplasia, Achondroplasia treatment, Vosoritide, PRECICE, PRECICE system, Ilizarov apparatus, Short stature treatment, C-type natriuretic peptide, Growth hormone, Meclozine, Bowed legs, Spinal surgery, Surgical limb lengtheningAbstract
Introduction and Purpose:
Achondroplasia, the most common form of dwarfism, results from mutations in the FGFR3 gene. The disorder causes disproportionate short stature due to a gain-of-function mutation in FGFR3, impacting bone growth. Patients often face various health challenges, including orthopedic, neurological, and respiratory issues. This review aims to analyze current treatment strategies, their limitations, and highlight promising new approaches for managing achondroplasia.
Materials and Methods:
This review synthesizes available literature on the clinical management of achondroplasia, focusing on treatment modalities such as growth hormone therapy, limb lengthening techniques, spinal surgery, and gene therapies. Emphasis is placed on understanding the efficacy, challenges, and emerging therapies for this genetic condition.
Results:
Current treatment approaches include recombinant human growth hormone (rhGH) therapy, which has shown modest success in increasing height but has limited long-term benefits. Limb lengthening remains a cornerstone for improving quality of life, with techniques like the Ilizarov method and PRECICE system, though complications and high costs persist. Spinal surgeries for foramen magnum stenosis and kyphosis provide relief but are complex and require individualized care. New treatments like Vosoritide, a CNP analogue, show promise by promoting bone growth. Gene-editing techniques like CRISPR/Cas9 offer potential for correcting the underlying genetic mutations.
Conclusion:
Achondroplasia management continues to evolve with a combination of surgical, pharmacological, and genetic interventions. While limb lengthening and spinal surgeries significantly improve quality of life, new treatments like Vosoritide and CRISPR/Cas9 may revolutionize care by addressing the root cause of the condition. Ongoing research and clinical trials will likely refine these approaches, offering better outcomes for patients with achondroplasia.
References
1. Pauli RM. Achondroplasia: a comprehensive clinical review. Orphanet J Rare Dis. 2019 Jan 3;14(1):1. doi: 10.1186/s13023-018-0972-6. PMID: 30606190.
2. Ornitz DM, Legeai-Mallet L. Achondroplasia: Development, pathogenesis, and therapy. Dev Dyn. 2017 Apr;246(4):291-309. doi: 10.1002/dvdy.24479. Epub 2017 Mar 2. PMID: 27987249
3. Murton MC, Drane ELA, Goff-Leggett DM, Shediac R, O'Hara J, Irving M, Butt TJ. Burden and Treatment of Achondroplasia: A Systematic Literature Review. Adv Ther. 2023 Sep;40(9):3639-3680. doi: 10.1007/s12325-023-02549-3. Epub 2023 Jun 29. PMID: 37382866
4. de Vries OM, Johansen H, Fredwall SO. Physical fitness and activity level in Norwegian adults with achondroplasia. Am J Med Genet A. 2021 Apr;185(4):1023-1032. doi: 10.1002/ajmg.a.62055. Epub 2020 Dec 31. PMID: 33382213
5. Wrobel W, Pach E, Ben-Skowronek I. Advantages and Disadvantages of Different Treatment Methods in Achondroplasia: A Review. Int J Mol Sci. 2021 May 25;22(11):5573. doi: 10.3390/ijms22115573. PMID: 34070375
6. Savarirayan R. International Consensus Statement on the diagnosis, multidisciplinary management and lifelong care of individuals with achondroplasia. Nat Rev Endocrinol. 2022. DOI: 10.1038/s41574-021-00595-x PMID: 34837063
7. Verdoni F, Giorgino R, Virgilio C, Nannini A, Viganò M, Curci D, Peretti GM, Mangiavin Results and complications of bilateral limb lengthening in achondroplasia: a retrospective analysis. Front Pediatr. 2023 Nov 3;11:1281099. doi: 10.3389/fped.2023.1281099. eCollection 2023. PMID: 38027309
8. M DE MEZER. HISTORY OF RESEARCH ON GENESIS AND HISTORY OF ACHONDROPLASIA’S TREATMENT Nowiny Lekarskie 2009, 78, 5–6, 368–370
9. Zhu YL, Guo BF, Zang JC, Pan Q, Zhang DW, Peng Y, Qin SH. Ilizarov technology in China: a historic review of thirty-one years. Int Orthop. 2022 Mar;46(3):661-668. doi: 10.1007 s00264-021-05238-4. Epub 2021 Oct 13. PMID: 34647137
10. Gubin AV, Borzunov DY, Malkova TA. The Ilizarov paradigm: thirty years with the Ilizarov method, current concerns and future research. Int Orthop. 2013 Aug;37(8):1533-9. doi: 10.1007/s00264-013-1935-0. Epub 2013 May 28. PMID: 23712212
11. Young C, Adcock L. PRECICE Intramedullary Limb Lengthening System: A Review of Clinical Effectiveness [Internet] Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Dec 7. PMID: 30260605
12. Limb lengthening with PRECICE magnetic nail in pediatric patients: A systematic review. 2021 Aug 18;12(8):575-583. doi: 10.5312/wjo.v12.i8.575. PMID: 34485104
13. Paley D. Extensive Limb Lengthening for Achondroplasia and Hypochondroplasia Cildren (Basel). 2021 Jun 24;8(7):540. doi: 10.3390/children8070540. PMID: 34202538
14. Savarirayan R, Ireland P, Irving M, Thompson D, Alves I, Baratela WAR, Betts J, Bober MB, Boero S, Briddell J, Campbell J, Campeau PM, Carl-Innig P, Cheung MS, Cobourne M, Cormier-Daire V, Deladure-Molla M, Del Pino M, Elphick H, Fano V, Fauroux B, Gibbins J, Groves ML, Hagenäs L, Hannon T, Hoover-Fong J, Kaisermann M, Leiva-Gea A, Llerena J, Mackenzie W, Martin K, Mazzoleni F, McDonnell S, Meazzini MC, Milerad J, Mohnike K, Mortier GR, Offiah A, Ozono K, Phillips JA 3rd, Powell S, Prasad Y, Raggio C, Rosselli P, Rossiter J, Selicorni A, Sessa M, Theroux M, Thomas M, Trespedi L, Tunkel D, Wallis C, Wright M, Yasui N, Fredwall SO. International Consensus Statement on the diagnosis, multidisciplinary management and lifelong care of individuals with achondroplasia. Nat Rev Endocrinol. 2022 Mar;18(3):173-189. doi: 10.1038/s41574-021-00595-x. Epub 2021 Nov 26. PMID: 34837063
15. Kubota T, Adachi M, Kitaoka T, Hasegawa K, Ohata Y, Fujiwara M, Michigami T, Mochizuki H, Ozono K. Clinical Practice Guidelines for Achondroplasia. Clin Pediatr Endocrinol. 2020;29(1):25-42. doi: 10.1297/cpe.29.25. Epub 2020 Jan 9. PMID: 32029970
16. McDonald EJ, De Jesus O. Achondroplasia. 2023 Aug 23. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 32644689
17. Abu Al-Rub Z, Lineham B, Hashim Z, Stephenson J, Arnold L, Campbell J, Loughenbury P, Khan A. Surgical treatment of spinal stenosis in achondroplasia: Literature review comparing results in adults and paediatrics. J Clin Orthop Trauma. 2021 Oct 30;23:101672. doi: 10.1016/j.jcot.2021.101672. eCollection 2021 Dec. PMID: 34790562
18. Ok MS, Nagaraj UD, Mahmoud M. Foramen Magnum Stenosis and Spinal Cord Compression in Achondroplasia. Anesthesiology. 2019 Aug;131(2):396. doi: 10.1097/ALN.0000000000002757.
PMID: 31094747
19. Collins WO, Choi SS. Otolaryngologic manifestations of achondroplasia. Arch Otolaryngol Head Neck Surg. 2007 Mar;133(3):237-44. doi: 10.1001/archotol.133.3.237. PMID: 17372080
20. Fafilek B, Bosakova M, Krejci P. Expanding horizons of achondroplasia treatment: current options and future developments. Osteoarthritis Cartilage. 2022 Apr;30(4):535-544. doi: 10.1016/j.joca.2021.11.017. Epub 2021 Dec 2. PMID: 34864168
21. Dauber A, Zhang A, Kanakatti Shankar R, Boucher K, McCarthy T, Shafaei N, Seaforth R, Castro MG, Dham N, Merchant N. Vosoritide treatment for children with hypochondroplasia: a phase 2 trial. EClinicalMedicine. 2024 Apr 11;71:102591. doi: 10.1016/j.eclinm.2024.102591. eCollection 2024 May. PMID: 38813446
22. Savarirayan R, Hoernschemeyer D G, Ljungberg M, Zarate Y A, Bacino C A et al.
Once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACcomplisH): a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-escalation trial. ClinicalMedicine. 2023 Oct 2:65:102258. doi: 10.1016/j.eclinm.2023.102258. eCollection 2023 Nov. PMID: 37823031
23. Zou H, Guan M, Li Y, Luo F, Wang W, Qin Y. Targeted gene correction and functional recovery in achondroplasia patient-derived iPSCs . Stem Cell Res Ther. 2021 Aug 28;12(1):485. doi: 10.1186/s13287-021-02555-8. PMID: 34454631
24. Miao K, Zhang X, Su SM, Zeng J, Huang Z, Chan UI, Xu X, Deng CX. Optimizing CRISPR/Cas9 technology for precise correction of the Fgfr3-G374R mutation in achondroplasia in mice. J Biol Chem. 2019 Jan 25;294(4):1142-1151. doi: 10.1074/jbc.RA118.006496. Epub 2018 Nov 28.
PMID: 30487289
25. Wojtal D, Kemaladewi DU, Malam Z, Abdullah S, Wong TW, Hyatt E, Baghestani Z, Pereira S, Stavropoulos J, Mouly V, Mamchaoui K, Muntoni F, Voit T, Gonorazky HD, Dowling JJ, Wilson MD, Mendoza-Londono R, Ivakine EA, Cohn RD. Spell Checking Nature: Versatility of CRISPR/Cas9 for Developing Treatments for Inherited Disorders. Am J Hum Genet. 2016 Jan 7;98(1):90-101. doi: 10.1016/j.ajhg.2015.11.012. Epub 2015 Dec 10. PMID: 26686765
26. Matsushita M, Kitoh H, Ohkawara B et al. Meclozine facilitates proliferation and differentiation of chondrocytes by attenuating abnormally activated FGFR3 signaling in achondroplasia. PLoS One. 2013;8(12):e81569. 10.1371/journal.pone.0081569
27. Matsushita M, Esaki R, Mishima K, Ishiguro N, Ohno K, Kitoh H. Clinical dosage of meclozine promotes longitudinal bone growth, bone volume, and trabecular bone quality in transgenic mice with achondroplasia. Sci Rep. 2017;7(1):7371. 10.1038/s41598-017-07044-8
28. Funahashi H, Matsushita M, Esaki R, Mishima K, Ohkawara B, Kamiya Y, Takegami Y, Ohno K, Kitoh H, Imagama S. Long-term oral meclozine administration improves survival rate and spinal canal stenosis during postnatal growth in a mouse model of achondroplasia in both sexes JBMR Plus. 2024 Feb 24;8(4):ziae018. doi: 10.1093/jbmrpl/ziae018. eCollection 2024 Apr. PMID: 38544920
29. Savarirayan R, De Bergua JM, Arundel P, McDevitt H, Cormier-Daire V, Saraff V, Skae M, Delgado B, Leiva-Gea A, Santos-Simarro F, Salles JP, Nicolino M, Rossi M, Kannu P, Bober MB, Phillips J 3rd, Saal H, Harmatz P, Burren C, Gotway G, Cho T, Muslimova E, Weng R, Rogoff D, Hoover-Fong J, Irving M. Infigratinib in children with achondroplasia: the PROPEL and PROPEL 2 studies. Ther Adv Musculoskelet Dis. 2022 Mar 21;14:1759720X221084848. doi: 10.1177/1759720X221084848. eCollection 2022. PMID: 35342457
30. Michel ZD, Aitken SF, Glover OD, Alejandro LO, Randazzo D, Dambkowski C, Martin D, Collins MT, Somerman MJ, Chu EY. Infigratinib, a selective FGFR1-3 tyrosine kinase inhibitor, alters dentoalveolar development at high doses. Dev Dyn. 2023 Dec;252(12):1428-1448. doi: 10.1002/dvdy.642. Epub 2023 Jul 12. PMID: 37435833
31. Gonçalves D, Rignol G, Dellugat P, Hartmann G, Sarrazy Garcia S, Stavenhagen J, Santarelli L, Gouze E, Czech C. In vitro and in vivo characterization of Recifercept, a soluble fibroblast growth factor receptor 3, as treatment for achondroplasia. PLoS One. 2020 Dec 28;15(12):e0244368. doi: 10.1371/journal.pone.0244368. eCollection 2020. PMID: 33370388
32. Rignol G, Garcia S, Authier F, Smith K, Tosello L, Marsault R, Dellugat P, Goncalves D, Brouillard M, Stavenhagen J, Santarelli L, Czech C, Gouze E. Longitudinal Imaging of the Skull Base Synchondroses Demonstrate Prevention of a Premature Ossification After Recifercept Treatment in Mouse Model of Achondroplasia. JBMR Plus. 2021 Nov 9;6(2):e10568. doi: 10.1002/jbm4.10568. eCollection 2022 Feb. PMID: 35229060
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Daria Bednarczyk, Wiktoria Pysiewicz, Wiktor Garbarczyk, Agnieszka Napieralska, Albert Kapla, Michalina Jurkiewicz, Julia Białeta, Katarzyna Rowińska, Karolina Siembab, Alicja Černohorská

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 103
Number of citations: 0